RE:079 to 079I think soon after the Conference Call this Wednesday we'll begin seeing a greater confidence is this Company's future. From what I'm seeing this company has a remarkable device for which there are millions of potential patients that would benefit and the procedure is simplistic and quick. Before Neovasc's "closing of Units, Common Shares, Warrants, and Concurrent Private Placement, which in part sold for $1.46 per unit, this stock was trading over $2.00. Two years ago the stock was at $12.00. I do believe we will revisit that again once a completion of the Tiara-11 Study and once we get moving on the COSIRA-11 IDE Study "a 385 patient to be conducted at up to 35 centers in the United States and which was recently approved by the FDA."